Last reviewed · How we verify
Beta Lactam Antibiotics
Beta Lactam Antibiotics is a Beta-lactam antibiotic Small molecule drug developed by Esraa Salah Mohamed Abdallah Eladl. It is currently in Phase 2 development for Bacterial infections. Also known as: Cefipim.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Used for Bacterial infections.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Anti-infectives pathway favourability
+2.0pp
Microbiological endpoints + non-inferiority designs raise approval rates above baseline.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Beta Lactam Antibiotics |
|---|---|
| Also known as | Cefipim |
| Sponsor | Esraa Salah Mohamed Abdallah Eladl |
| Drug class | Beta-lactam antibiotic |
| Target | Penicillin-binding proteins |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 2 |
Mechanism of action
Beta-lactam antibiotics work by inhibiting the synthesis of the bacterial cell wall, ultimately leading to cell lysis and death.
Approved indications
- Bacterial infections
Common side effects
- Allergic reactions
- Gastrointestinal disturbances
- Hypersensitivity reactions
Key clinical trials
- Comparison of Oral Antibiotics For Bone Infections of the Leg and Foot (PHASE4)
- Optimization of Beta-lactam Dosing in Critically Ill Patients With Cystatin C (OPTIMIZE-GNI) (PHASE4)
- Study of 2 Medicines (Aztreonam and Avibactam) Compared to Best Available Therapy for Serious Gram-negative Infections (PHASE2)
- Utility of Single-dose Oral Antibiotic Prophylaxis in Prevention of Surgical Site Infection in Dermatologic Surgery (PHASE4)
- Duration of Cardiac Antimicrobial Prophylaxis Outcomes Study (PHASE4)
- APLAUD Trial (Antibiotics vs PLacebo for Acute Uncomplicated Diverticulitis) (PHASE2)
- Antibiotic Use & Open Fracture of the Lower Extremity (PHASE3)
- Fast Track Therapeutic Model in Acute Complicated Appendicitis in Pediatrics (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Beta Lactam Antibiotics CI brief — competitive landscape report
- Beta Lactam Antibiotics updates RSS · CI watch RSS
- Esraa Salah Mohamed Abdallah Eladl portfolio CI
Frequently asked questions about Beta Lactam Antibiotics
What is Beta Lactam Antibiotics?
How does Beta Lactam Antibiotics work?
What is Beta Lactam Antibiotics used for?
Who makes Beta Lactam Antibiotics?
Is Beta Lactam Antibiotics also known as anything else?
What drug class is Beta Lactam Antibiotics in?
What development phase is Beta Lactam Antibiotics in?
What are the side effects of Beta Lactam Antibiotics?
What does Beta Lactam Antibiotics target?
Related
- Drug class: All Beta-lactam antibiotic drugs
- Target: All drugs targeting Penicillin-binding proteins
- Manufacturer: Esraa Salah Mohamed Abdallah Eladl — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Bacterial infections
- Also known as: Cefipim
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing